IGHS Group and Consult Invest celebrate a contract for Central Asian Countries.

The IGHS signed today, in Tashkent, Uzbekistan, a contract with the multinational Consult Invest, for the representation of services and products of Idealmed GHS and its brand new biothech company, Innov-Cell Therapeutics, for the Central Asian Countries.

This contract includes the design, development and management of hospitals in Uzbekistan and Kazakhstan, as well as the pharmaceutical distribution of Innov-Cell Therapeutics products for all the regions of Central Asia.

For José Alexandre Cunha, Chairman of IGHS Group "the celebration of this contract, which has the strong support of the local governments, demonstrates a great recognition of IGHS work and projects developed in the international market and represents a huge opportunity in a region that has shown a unique growth. Once again, we are able to assume that from Portugal, and in particular from Coimbra, it’s possible to strengthen our skills in a such competitive sector.
 

• Innov.Cell ended its successful participation in CPHI 2024

  Innov.Cell, a subsidiary of IGHS, ended its successful participation in CPHI 2024, which took place in Milan, with a positive outcome. This year, CPHI was attended by more than 62,000 people and around 2,400 exhibitors from 166 countries. Throughout the event, Innov.Cell met with several potential partners, from R&D, investors, and distributors covering more than 50 countries.

  Read more
• OIH Introduces Revolutionary Treatment for Keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS)

  Oman International Hospital is thrilled to announce the successful introduction of a groundbreaking procedure designed to treat keratoconus: Corneal Allogeneic Intrastromal Ring Implants (CAIRS). This innovative treatment marks a significant advancement in ophthalmology, offering new hope to patients suffering from this debilitating corneal disorder.
   

  Read more